March 3, 2026Open Access

Luteolin mitigates proliferative vitreoretinopathy through inhibition of ERK1/2 signaling and epithelial–mesenchymal transition

Key Points

Luteolin mitigates proliferative vitreoretinopathy (PVR) through significant inhibition of epithelial-mesenchymal transition.
In vitro studies indicate reduced RPE cell migration, correlating with a decrease in ERK1/2 signaling activity.
The findings suggest that luteolin has protective effects on retinal pigment epithelial cells during PVR development.
This work highlights luteolin’s potential as a therapeutic agent, requiring further studies to confirm efficacy.

Abstract

Luteolin suppresses RPE cell migration and EMT both in vitro and in vivo, thereby alleviating PVR development. Its protective effect is associated with downregulation of ERK1/2 signaling. The inhibitory effects of luteolin suggest its potential as a therapeutic agent for PVR.

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Authors

Lingdan Wu

Fei Liu

Jinghua Chai

Journals

Frontiers in Pharmacology

Actions

Institutions

Nanchang University

Guhua Hospital

References and Citations

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Luteolin mitigates proliferative vitreoretinopathy through inhibition of ERK1/2 signaling and epithelial–mesenchymal transition

Key Points

Abstract

Citation Network

Connected Papers

Discussion

Authors

Journals

Actions

Institutions

References and Citations

Citation Network

Connected Papers

Discussion

Cite this study